Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 2:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: rigosertib Clear all
Active, not recruiting Phase 2 Interventional

Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors

NCT05764395
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Refractory Melanoma, Unresectable Melanoma
Interventions
Rigosertib, Pembrolizumab, Magnetic Resonance Imaging, Biospecimen Collection, Biopsy
Drug · Biological · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 4, 2026, 2:15 AM EDT
Terminated Phase 2 Interventional Results available

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

NCT02730884
View directory record Official record
Conditions
Leukemia, Myelofibrosis, Anemia, Splenomegaly
Interventions
Rigosertib, Questionnaire
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Sep 4, 2026, 2:15 AM EDT
Completed Phase 1 Interventional

Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer

NCT01538537
View directory record Official record
Conditions
Advanced Cancer, Solid Tumors, Cancer, Neoplasms
Interventions
rigosertib sodium
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 4, 2026, 2:15 AM EDT
Completed Phase 2 Interventional

Oral Rigosertib for Squamous Cell Carcinoma

NCT01807546
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Skin Squamous Cell Carcinoma, Penile Squamous Cell Carcinoma
Interventions
rigosertib
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
13
States / cities
Sacramento, California • Stanford, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Sep 4, 2026, 2:15 AM EDT
Completed Phase 1 Interventional

Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors

NCT01168011
View directory record Official record
Conditions
Solid Tumor
Interventions
rigosertib
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 4, 2026, 2:15 AM EDT
Withdrawn Phase 1 Interventional

Three Dosing Schedules of Oral Rigosertib in MDS Patients

NCT02075034
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
rigosertib
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Sep 4, 2026, 2:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers

NCT02030639
View directory record Official record
Conditions
Healthy
Interventions
rigosertib
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 4, 2026, 2:15 AM EDT
Completed Phase 1 Interventional

Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma

NCT00861783
View directory record Official record
Conditions
Hepatoma, Advanced Solid Tumor
Interventions
irinotecan and ON 01910.Na, oxaliplatin and ON 01910.Na
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 4, 2026, 2:15 AM EDT
Completed Phase 1 Interventional

Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer

NCT02107235
View directory record Official record
Conditions
Head and Neck Neoplasms, Carcinoma, Squamous Cell
Interventions
oral rigosertib, cisplatin, Radiotherapy
Drug · Radiation
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Aurora, Colorado • Newark, Delaware • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 4, 2026, 2:15 AM EDT
Completed Phase 1 Interventional

Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin

NCT00861328
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ON 01910.Na and irinotecan, ON 01910.Na and oxaliplatin
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 4, 2026, 2:15 AM EDT
Completed Phase 2 Interventional

Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

NCT01904682
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Oral rigosertib
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
10
States / cities
Stanford, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Sep 4, 2026, 2:15 AM EDT
Completed Phase 3 Interventional

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

NCT01360853
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
ON 01910.Na, Gemcitabine
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
30
States / cities
La Jolla, California • Palm Springs, California • Salinas, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Sep 4, 2026, 2:15 AM EDT
Completed Phase 1 Interventional

Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors

NCT01125891
View directory record Official record
Conditions
Malignant Neoplasmas, Solid Tumors
Interventions
gemcitabine, ON 01910.Na
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Denver, Colorado • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 4, 2026, 2:15 AM EDT
Completed Phase 1 Interventional

Safety of ON 01910.Na in Patients With Myelodysplasia

NCT00533416
View directory record Official record
Conditions
Myelodysplastic Syndrome (MDS)
Interventions
ON 01910 Na
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 4, 2026, 2:15 AM EDT
Completed Phase 1Phase 2 Interventional

Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine

NCT01926587
View directory record Official record
Conditions
Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Interventions
oral rigosertib, Azacitidine
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
12
States / cities
Gilbert, Arizona • Duarte, California • Rancho Mirage, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Sep 4, 2026, 2:15 AM EDT
Terminated Phase 3 Interventional

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA

NCT02562443
View directory record Official record
Conditions
Myelodysplastic Syndrome, MDS, Refractory Anemia With Excess Blasts, RAEB
Interventions
rigosertib, Any approved or standard-of-care therapy, best supportive care (BSC)
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years to 81 Years
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
32
States / cities
La Jolla, California • Los Angeles, California • Fleming Island, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2022 · Synced Sep 4, 2026, 2:15 AM EDT
Completed Phase 2 Interventional Results available

Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients

NCT00856791
View directory record Official record
Conditions
Ovarian Cancer
Interventions
ON 01910.Na
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 4, 2026, 2:15 AM EDT
Completed Phase 3 Interventional

Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts

NCT01241500
View directory record Official record
Conditions
Myelodysplastic Syndromes, MDS, RAEB, Chronic Myelomonocytic Leukemia
Interventions
ON 01910.Na
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
41
States / cities
Scottsdale, Arizona • La Jolla, California • Stanford, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Sep 4, 2026, 2:15 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome

NCT01584531
View directory record Official record
Conditions
Myelodysplastic Syndrome, MDS, Trisomy 8
Interventions
rigosertib
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Sep 4, 2026, 2:15 AM EDT
Completed Phase 1 Interventional

A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies

NCT00861510
View directory record Official record
Conditions
Lymphoma, Mantle-cell, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Hairy Cell, Waldenstrom Macroglobulinemia, Multiple Myeloma
Interventions
ON01910 Na
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Sep 4, 2026, 2:15 AM EDT
Completed Phase 1 Interventional

Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer

NCT01538563
View directory record Official record
Conditions
Solid Tumors, Advanced Cancer, Cancer, Neoplasms
Interventions
rigosertib sodium
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 4, 2026, 2:15 AM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome

NCT01048619
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
ON 01910.Na
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Tampa, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 4, 2026, 2:15 AM EDT
Completed Early Phase 1 Interventional

Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC

NCT04177498
View directory record Official record
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
Rigosertib Sodium, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 79 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Sep 4, 2026, 2:15 AM EDT
Completed Phase 1 Interventional

Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)

NCT00854646
View directory record Official record
Conditions
Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Chronic Myelocytic Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes
Interventions
ON 01910.Na
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Sep 4, 2026, 2:15 AM EDT